CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-07 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −945 | 15,324 | ||
| 2024-03-07 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,030 | 101,510 | ||
| 2024-03-04 | Dable Habib J Director | Grant or award · Stock Option (Right to Buy) | +1,531 | $16.37 | $25K | 1,531 |
| 2024-02-23 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +511 | $1.74 | $889 | 3,762 |
| 2024-02-23 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −511 | $19.50 | $10K | 3,251 |
| 2024-02-23 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −511 | 3,014 | ||
| 2024-02-20 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +3,489 | $1.74 | $6K | 6,740 |
| 2024-02-20 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −2,591 | $20.11 | $52K | 4,149 |
| 2024-02-20 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −898 | $20.58 | $18K | 3,251 |
| 2024-02-20 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,502 | 3,525 | ||
| 2024-02-20 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −987 | 8,036 | ||
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +1,400 | $1.74 | $2K | 3,009 |
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +3,200 | $2.14 | $7K | 6,209 |
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −4,600 | $17.45 | $80K | 1,609 |
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −900 | 13,308 | ||
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 9,088 | ||
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 10,894 | ||
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,200 | 34,908 | ||
| 2024-02-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 41,732 | ||
| 2024-01-29 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 |
Page 8 of 16 · 315 trades